Showing 6401-6410 of 8179 results for "".
- PsO Pipeline Update: First Cohort of Patients Dosed with LNK01004 in Phase Ib Studyhttps://practicaldermatology.com/news/pso-pipeline-update-first-cohort-of-patients-dosed-with-lnk01004-in-phase-ib-study/2461742/The first cohort of psoriatic patients have been dosed in a Phase Ib clinical trial of Lynk Pharmaceuticals Co., Ltd.’s LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese p
- Almirall, CRG Partner to Develop Novel Preclinical Models for NMSChttps://practicaldermatology.com/news/almirall-crg-partner-to-develop-novel-preclinical-models-for-nmsc/2461741/Almirall and the Centre for Genomic Regulation (CRG) are joining forces to develop and characterize novel preclinical models that will help identify new treatments for non-melanoma skin cancer (NMSC). This partnership, led by Almirall's investigators Dr
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven
- It's Going to Be a Scorcher: Experts Predict Extreme UV Index Ratings This Memorial Dayhttps://practicaldermatology.com/news/its-going-to-be-a-scorcher-experts-predict-extreme-uv-index-ratings-this-memorial-day/2461739/A dozen U.S. cities are expected to have extreme ultraviolet (UV) index ratings (10+) this Memorial Day and throughout the summer, according to data from the
- SCALE News: Optimize Your Results with Radiofrequency Microneedlinghttps://practicaldermatology.com/news/radiofrequency-microneedling-optimize-your-results-1/2461731/For optimal results when treating patients with radiofrequency (RF) microneedling, anecdotal and personal experience guide Elizabeth L. Tanzi, MD, as there are “no significant comparison studies to date” on the
- ASA Awards: Jon M. Hanifin, MD, Wins David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/asa-awards-jon-m-hanifin-md-wins-david-martin-carter-mentor-award/2461728/The American Skin Association (ASA) announced the recipients of the 2023 David Martin Carter Mentor Award, 2023 George W. Hambrick Award, and the 2023 Research Achievement Awards at the International Societies for Investigative Dermatology (ISID) in Tokyo, Japan. <
- Study: Spironolactone May Be an Alternative to Antibiotics for Women With Persistent Acnehttps://practicaldermatology.com/news/study-spironolactone-may-be-an-alternative-to-antibiotics-for-women-with-persistent-acne/2461725/Spironolactone could be a cheap and readily available alternative to antibiotics for women with persistent acne, according to research out of the University of Southampton. The results of the trial appear in the Bri
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development a
- First Subject Dosed in Phase 1 Clinical Study of NM26 for ADhttps://practicaldermatology.com/news/first-subject-dosed-in-phase-1-clinical-study-of-nm26-for-ad/2461718/The first subject has been dosed in the Phase 1 clinical study of Numab Therapeutics’ NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD). This marks the beginning of a combined single ascending dose (SAD) and multip
- Rare Skin Disease Update: Abeona's EB-101 Performs Well in a Phase 3 study of RDEBhttps://practicaldermatology.com/news/rare-skin-disease-update-abeonas-eb-101-performs-well-in-a-phase-3-study-of-rdeb/2461715/Abeona Therapeutics Inc.’s investigational EB-101 performed well in a Phase 3 study of recessive dystrophic epidermolysis bullosa (RDEB). Both co-primary endpoints were met, with the majority (81.4%) of randomized EB-101–treated wounds demonstrating ≥50% healing compared